Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Leases (2020 - 2025)

Historic Current Leases for Revolution Medicines (RVMD) over the last 6 years, with Q3 2025 value amounting to $16.3 million.

  • Revolution Medicines' Current Leases rose 9444.97% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 9444.97%. This contributed to the annual value of $12.9 million for FY2024, which is 7467.77% up from last year.
  • Per Revolution Medicines' latest filing, its Current Leases stood at $16.3 million for Q3 2025, which was up 9444.97% from $13.1 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Current Leases peaked at $16.3 million during Q3 2025, and registered a low of $3.7 million during Q1 2021.
  • For the 5-year period, Revolution Medicines' Current Leases averaged around $7.9 million, with its median value being $6.8 million (2022).
  • As far as peak fluctuations go, Revolution Medicines' Current Leases crashed by 1798.49% in 2023, and later soared by 9444.97% in 2025.
  • Over the past 5 years, Revolution Medicines' Current Leases (Quarter) stood at $6.2 million in 2021, then rose by 9.0% to $6.8 million in 2022, then grew by 8.8% to $7.4 million in 2023, then surged by 74.68% to $12.9 million in 2024, then rose by 26.83% to $16.3 million in 2025.
  • Its Current Leases stands at $16.3 million for Q3 2025, versus $13.1 million for Q2 2025 and $13.0 million for Q1 2025.